A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer
about
Emerging roles of PDGF-D in EMT progression during tumorigenesisRegulation of feto-maternal barrier by matriptase- and PAR-2-mediated signaling is required for placental morphogenesis and mouse embryonic survivalMice Lacking Platelet-Derived Growth Factor D Display a Mild Vascular PhenotypeReduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activationPlatelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Matriptase zymogen supports epithelial development, homeostasis and regenerationAkt- and Erk-mediated regulation of proliferation and differentiation during PDGFRβ-induced MSC self-renewalDiversity of matriptase expression level and function in breast cancer.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Targeting the PDGF signaling pathway in tumor treatmentThe host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine.Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cellsDynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors.Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesisPTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancerMatriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in LactationCediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reactionPDGF-D gene polymorphism is associated with increased cardiovascular mortality in elderly men.A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growthA critical role of the PTEN/PDGF signaling network for the regulation of radiosensitivity in adenocarcinoma of the prostate.Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.Matriptase expression and zymogen activation in human pilosebaceous unit.Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.The matriptase-prostasin proteolytic cascade in epithelial development and pathology.Autocrine PDGF stimulation in malignancies.Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Mechanisms of hepatocyte growth factor activation in cancer tissues.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (Prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer.The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
P2860
Q26859634-418719F1-92FC-4251-8311-AB59951B727EQ27314964-E46208F4-15AC-458C-9EBA-17E94093AC3BQ27316378-924D9547-E3FB-48EF-93EF-10E2C984064DQ28483094-0F20D4FD-B909-4290-8C82-B0F89B7C2FAFQ29347051-1C536D61-EE14-4EAA-BD1E-8ECB0A06913BQ33415009-6D0B29E0-615A-4356-8EBF-29DAB63B9AABQ33749952-40E4B981-A2A7-4C15-8A65-9D3EA4A71149Q33986004-091AA7A9-4CC1-451B-9D7A-C756A59F349AQ34238503-26395331-6186-43EB-A2E5-DCE8919E0122Q34352802-FB3B9817-D314-41CC-8A9F-1D20F4BE80A5Q34393461-FA79161A-774F-495A-8578-4DCEED3D2D16Q34699785-206160CF-FB09-4FFA-8F9D-9FCB98F3A428Q35102675-452AC3C7-BAAF-4F8C-B40F-29AD70B42F39Q35120213-88D5F07E-CAB8-4DA1-8FBC-9737E2758D6DQ35191957-F2C6578F-0F7A-43FB-81A6-CD266FCD0A62Q35580879-2A5D3C19-8EE1-4C94-BE1A-8A4C1EB0886AQ35663624-30A2A1BD-5E8F-434C-9D23-C823EC162E00Q35666129-612BC20E-0264-4794-9868-B5704B352324Q35696184-B9DBABCD-2877-4ADE-BAF0-BC6A0012B43FQ35823094-D62A9AB2-98B3-46D3-9699-CFAECD43DFDFQ35952035-75B34B85-A8A7-435C-ABBF-1346A543DC10Q35979337-79FC5219-F362-4529-A063-C161890FBC7AQ36013452-D85FAD6F-7C22-4D1A-A580-803D8A23577CQ36120513-D5E8380B-F731-490F-9DDC-ED23FD908356Q36352562-26D69EDC-58D6-499E-9F5A-470D656B0C01Q37035984-1DFFB8F8-0A34-48C3-80D8-430DEDE65D2AQ37184447-8E345A5D-F8C5-4F3A-8826-500A46018162Q37218017-DCAE641B-CFB4-4086-936D-F6C29EACB1C0Q37218234-70E52A65-B8A6-4136-871D-AAA8FE988037Q37416285-B9E60402-E261-49B2-93B4-616B70A7FAD7Q37593021-9FD7C10F-E73F-4D4D-A7D7-7CF6DB3179BDQ37986624-83685193-4758-4F8A-A3C2-331DB4B4CA69Q38003387-79FC0608-DA67-438F-8CE1-8384542CA78BQ38160946-CBD39DCE-A8A3-4C94-A587-421895D23BBCQ38184632-CA2B98EE-E79A-4440-B574-9F9128025181Q38255480-13EF6036-67CD-4BAC-AE54-A5941205C5C3Q38258904-8FB6175D-8335-46B3-8530-8E30F4743DC7Q38746986-D45E94AE-E767-4E82-836B-AA5F911C1685Q38771773-35AB494F-98BF-4763-B943-787DC7AB37A1Q38806364-4D92D17D-9DF4-4401-A526-47E626830D60
P2860
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer
@en
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@ast
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@nl
type
label
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer
@en
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@ast
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@nl
prefLabel
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer
@en
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@ast
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@nl
P2093
P2860
P1433
P1476
A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.
@en
P2093
Carolyn V Ustach
Chen-Yong Lin
Hyeong-Reh Choi Kim
Judith Abrams
Mingxin Che
P2860
P304
P356
10.1158/0008-5472.CAN-10-0511
P407
P577
2010-11-23T00:00:00Z